Bachem AG

Bubendorf, Switzerland

Bachem AG

Bubendorf, Switzerland
SEARCH FILTERS
Time filter
Source Type

Dhayalan B.,University of Chicago | Mandal K.,University of Chicago | Rege N.,Case Western Reserve University | Weiss M.A.,Case Western Reserve University | And 4 more authors.
Chemistry - A European Journal | Year: 2017

We have systematically explored three approaches based on 9-fluorenylmethoxycarbonyl (Fmoc) chemistry solid phase peptide synthesis (SPPS) for the total chemical synthesis of the key depsipeptide intermediate for the efficient total chemical synthesis of insulin. The approaches used were: stepwise Fmoc chemistry SPPS; the “hybrid method”, in which maximally protected peptide segments made by Fmoc chemistry SPPS are condensed in solution; and, native chemical ligation using peptide-thioester segments generated by Fmoc chemistry SPPS. A key building block in all three approaches was a Glu[O-β-(Thr)] ester-linked dipeptide equipped with a set of orthogonal protecting groups compatible with Fmoc chemistry SPPS. The most effective method for the preparation of the 51 residue ester-linked polypeptide chain of ester insulin was the use of unprotected peptide-thioester segments, prepared from peptide-hydrazides synthesized by Fmoc chemistry SPPS, and condensed by native chemical ligation. High-resolution X-ray crystallography confirmed the disulfide pairings and three-dimensional structure of synthetic insulin lispro prepared from ester insulin lispro by this route. Further optimization of these pilot studies could yield an efficient total chemical synthesis of insulin lispro (Humalog) based on peptide synthesis by Fmoc chemistry SPPS. © 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim


Schnitzer T.,ETH Zurich | Wiesner M.,ETH Zurich | Wiesner M.,Bachem AG | Krattiger P.,ETH Zurich | And 3 more authors.
Organic and Biomolecular Chemistry | Year: 2017

From an enzymatic perspective, there is a general notion that the bigger and more complex a catalytically active peptide is the more enzyme-like and the better it should become. But is this really true? We have tackled this question firstly by screening split-and-mix-libraries of tri- and tetrapeptides for members that catalyze aldol reactions. Then, the catalytic performance of all possible diastereoisomers of related tri- and tetrapeptidic catalysts of the type H-Pro-Pro-Glu/Asp-NH2 and H-Pro-Pro-Glu/Asp-Pro-NH2 in aldol and conjugate addition reactions was compared. © The Royal Society of Chemistry 2017.


News Article | December 5, 2016
Site: www.newsmaker.com.au

Wiseguyreports.Com Adds “Healthcare Supply Chain -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Healthcare Supply Chain in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Healthcare Supply Chain in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Healthcare Supply Chain in each application, can be divided into Application 1 Application 2 Application 3 Global Healthcare Supply Chain Sales Market Report 2016 1 Healthcare Supply Chain Overview 1.1 Product Overview and Scope of Healthcare Supply Chain 1.2 Classification of Healthcare Supply Chain 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Healthcare Supply Chain 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Healthcare Supply Chain Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Healthcare Supply Chain (2011-2021) 1.5.1 Global Healthcare Supply Chain Sales and Growth Rate (2011-2021) 1.5.2 Global Healthcare Supply Chain Revenue and Growth Rate (2011-2021) 7 Global Healthcare Supply Chain Manufacturers Analysis 7.1 Bayer 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Healthcare Supply Chain Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 Bayer Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Pfizer 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 119 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Pfizer Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 Merck Corporation 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 130 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 Merck Corporation Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 BASF 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Dec Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 BASF Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Bachem 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Bachem Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Johnson & Johnson 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Johnson & Johnson Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Decartis 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Pharma & Healthcare Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 Decartis Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 Roche 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 Roche Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Sanofi-Aventis 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 Sanofi-Aventis Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 GSK 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 GSK Healthcare Supply Chain Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 Astrazeneca 7.12 Eli Lilly 7.13 AMPAC Fine Chemicals


News Article | November 23, 2016
Site: www.newsmaker.com.au

This report studies Healthcare Supply Chain in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering  Bayer  Pfizer  Merck Corporation  BASF  Bachem  Johnson & Johnson  Novartis  Roche  Sanofi-Aventis  GSK  Astrazeneca  Eli Lilly  AMPAC Fine Chemicals Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Healthcare Supply Chain in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Type I  Type II  Type III Split by application, this report focuses on consumption, market share and growth rate of Healthcare Supply Chain in each application, can be divided into  Application 1  Application 2  Application 3 Global Healthcare Supply Chain Market Research Report 2016  1 Healthcare Supply Chain Market Overview  1.1 Product Overview and Scope of Healthcare Supply Chain  1.2 Healthcare Supply Chain Segment by Type  1.2.1 Global Production Market Share of Healthcare Supply Chain by Type in 2015  1.2.2 Type I  1.2.3 Type II  1.2.4 Type III  1.3 Healthcare Supply Chain Segment by Application  1.3.1 Healthcare Supply Chain Consumption Market Share by Application in 2015  1.3.2 Application 1  1.3.3 Application 2  1.3.4 Application 3  1.4 Healthcare Supply Chain Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Healthcare Supply Chain (2011-2021) 7 Global Healthcare Supply Chain Manufacturers Profiles/Analysis  7.1 Bayer  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 Healthcare Supply Chain Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 Bayer Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.1.4 Main Business/Business Overview  7.2 Pfizer  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 Healthcare Supply Chain Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 Pfizer Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 Merck Corporation  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 Healthcare Supply Chain Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 Merck Corporation Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 BASF  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 Healthcare Supply Chain Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 BASF Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.4.4 Main Business/Business Overview  7.5 Bachem  7.5.1 Company Basic Information, Manufacturing Base and Its Competitors  7.5.2 Healthcare Supply Chain Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 Bachem Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.5.4 Main Business/Business Overview  7.6 Johnson & Johnson  7.6.1 Company Basic Information, Manufacturing Base and Its Competitors  7.6.2 Healthcare Supply Chain Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 Johnson & Johnson Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.6.4 Main Business/Business Overview  7.7 Novartis  7.7.1 Company Basic Information, Manufacturing Base and Its Competitors  7.7.2 Healthcare Supply Chain Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 Novartis Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.7.4 Main Business/Business Overview  7.8 Roche  7.8.1 Company Basic Information, Manufacturing Base and Its Competitors  7.8.2 Healthcare Supply Chain Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 Roche Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.8.4 Main Business/Business Overview  7.9 Sanofi-Aventis  7.9.1 Company Basic Information, Manufacturing Base and Its Competitors  7.9.2 Healthcare Supply Chain Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II  7.9.3 Sanofi-Aventis Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.9.4 Main Business/Business Overview  7.10 GSK  7.10.1 Company Basic Information, Manufacturing Base and Its Competitors  7.10.2 Healthcare Supply Chain Product Type, Application and Specification  7.10.2.1 Type I  7.10.2.2 Type II  7.10.3 GSK Healthcare Supply Chain Production, Revenue, Price and Gross Margin (2015 and 2016)  7.10.4 Main Business/Business Overview  7.11 Astrazeneca  7.12 Eli Lilly  7.13 AMPAC Fine Chemicals


Padhi S.K.,University of Minnesota | Padhi S.K.,University of Greifswald | Fujii R.,University of Minnesota | Fujii R.,Mitsui Chemicals Inc. | And 5 more authors.
Chemistry and Biology | Year: 2010

The α/β hydrolase superfamily contains mainly esterases, which catalyze hydrolysis, but also includes hydroxynitrile lyases, which catalyze addition of cyanide to aldehydes, a carbon-carbon bond formation. Here, we convert a plant esterase, SABP2, into a hydroxynitrile lyase using just two amino acid substitutions. Variant SABP2-G12T-M239K lost the ability to catalyze ester hydrolysis (<0.9 mU/mg) and gained the ability to catalyze the release of cyanide from mandelonitrile (20 mU/mg, kcat/KM = 70 min-1M-1). This variant also catalyzed the reverse reaction, formation of mandelonitrile with low enantioselectivity: 20% ee (S), E = 1.5. The specificity constant for the lysis of mandelontrile is 13,000-fold faster than the uncatalyzed reaction and only 1300-fold less efficient (k cat/KM) than hydroxynitrile lyase from rubber tree. © 2010 Elsevier Ltd.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMP-08-2014 | Award Amount: 8.44M | Year: 2015

MACIVIVA is a highly interdisciplinary consortium among well established and innovative SMEs with scientific excellence and complementary industrial world-leading experts with unique expertise and know-how in virosome technology, spray and freeze drying, large scale manufacturing and packaging. MACIVIVA will pave the path to other large scale thermostable nanopharmaceuticals products for therapeutic and prophylactic vaccines and other potential applications for direct application by non-invasive routes. Liquid products are inherently prone to physical and/or chemical modifications and degradations. Solid vaccine dosage formats (e.g. powder) may prevent molecular motion and shear-induced degradation, and slow down degradation involving water and oxygen radicals, resulting in improved stability and enhanced shelf-life of vaccines. The cold chain storage is still fundamental for preserving the bioactivity of most liquid and freeze-dried vaccines, and a reconstitution step prior to administration is required for freeze dried vaccines that are usually administered intramuscularly or subcutaneously. These reconstituted freeze dried vaccines harbor important instability and must be used within hours and kept refrigerated. Because most liquid and reconstituted freeze-dried vaccines are susceptible to degradations, it may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection. For addressing liquid virosome-based vaccine instability and improving their shelf-life outside the cold chain, MACIVIVA will explore new galenic vaccine formulations through careful screening of excipients, stabilization and drying methods for generating new vaccine solid forms that can be easily self-administered. Robust universal manufacturing processes for upscale production of virosome dried powder for the non-invasive intranasal, oral and sublingual routes should be achieved by month 42.


PubMed | Bachem AG, Case Western Reserve University and University of Chicago
Type: | Journal: Chemistry (Weinheim an der Bergstrasse, Germany) | Year: 2016

We have systematically explored three approaches based on 9-fluorenylmethoxycarbonyl (Fmoc) chemistry solid phase peptide synthesis (SPPS) for the total chemical synthesis of the key depsipeptide intermediate for the efficient total chemical synthesis of insulin. The approaches used were: stepwise Fmoc chemistry SPPS; the hybrid method, in which maximally protected peptide segments made by Fmoc chemistry SPPS are condensed in solution; and, native chemical ligation using peptide-thioester segments generated by Fmoc chemistry SPPS. A key building block in all three approaches was a Glu[O--(Thr)] ester-linked dipeptide equipped with a set of orthogonal protecting groups compatible with Fmoc chemistry SPPS. The most effective method for the preparation of the 51 residue ester-linked polypeptide chain of ester insulin was the use of unprotected peptide-thioester segments, prepared from peptide-hydrazides synthesized by Fmoc chemistry SPPS, and condensed by native chemical ligation. High-resolution X-ray crystallography confirmed the disulfide pairings and three-dimensional structure of synthetic insulin lispro prepared from ester insulin lispro by this route. Further optimization of these pilot studies could yield an efficient total chemical synthesis of insulin lispro (Humalog) based on peptide synthesis by Fmoc chemistry SPPS.


Rentsch D.,Empa - Swiss Federal Laboratories for Materials Science and Technology | Stahelin C.,Bachem AG | Obkircher M.,Bachem AG | Hany R.,Empa - Swiss Federal Laboratories for Materials Science and Technology | And 4 more authors.
ACS Combinatorial Science | Year: 2012

The quality of preloaded Wang resins is very important for the success of solid-phase peptide syntheses (SPPS). A critical factor is the capping of remaining hydroxyl groups after loading with the first amino acid, since these free alcohols lead to truncated sequences during the following SPPS steps. Because the detection of hydroxyl groups by color tests is difficult and unreliable, the capping efficiency is often controlled by time-consuming peptide test syntheses. Here, we describe a two-dimensional, high resolution magic angle spinning NMR method for the quantitative determination of remaining 4-alkoxybenzyl alcohols in Fmoc-Xaa-Wang resins with a detection limit of 1 mol-%. The NMR method was validated with samples of known ratios between Fmoc-Ala-Wang and 4-alkoxybenzylalcohol resin. Application to a set of preloaded Fmoc-Ala- and Fmoc-Thr(tBu)-Wang test resins demonstrated that the full range of essential amino acids can be quantified without further spectrometer calibration. Compared to established test synthesis protocols, the NMR method represents not only advantages in terms of time and cost savings but also eliminates all inaccuracies due to further sample treatment like SPPS and cleavage from the resin. © 2012 American Chemical Society.


Giese B.,University of Fribourg | Kracht S.,University of Fribourg | Cordes M.,Bachem AG
Chimia | Year: 2013

Nature uses peptide aggregates as soft materials for electron transfer over long distances. These reactions occur in a multistep hopping reaction with various functional groups as relay stations that are located in the side chain and in the backbone of the peptides. © Schweizerische Chemische Gesellschaft.


News Article | November 11, 2016
Site: www.newsmaker.com.au

Notes:  Sales, means the sales volume of Acetylcysteine  Revenue, means the sales value of Acetylcysteine This report studies sales (consumption) of Acetylcysteine in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering  ZAMBON  Nippon Rika  Arevi Pharma  Bachem AG  Reekon  Shanghai Pharma  Minsheng Pharma  Guangdong Baiao Pharma  Conba Pharma  Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Acetylcysteine in these regions, from 2011 to 2021 (forecast), like  United States  China  Europe  Japan  Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into  JP  USP  EP  Split by applications, this report focuses on sales, market share and growth rate of Acetylcysteine in each application, can be divided into  COPD  CB  Other Global Acetylcysteine Sales Market Report 2016  1 Acetylcysteine Overview  1.1 Product Overview and Scope of Acetylcysteine  1.2 Classification of Acetylcysteine  1.2.1 JP  1.2.2 USP  1.2.3 EP  1.3 Application of Acetylcysteine  1.3.1 COPD  1.3.2 CB  1.3.3 Other  1.4 Acetylcysteine Market by Regions  1.4.1 United States Status and Prospect (2011-2021)  1.4.2 China Status and Prospect (2011-2021)  1.4.3 Europe Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.5 Global Market Size (Value and Volume) of Acetylcysteine (2011-2021)  1.5.1 Global Acetylcysteine Sales and Growth Rate (2011-2021)  1.5.2 Global Acetylcysteine Revenue and Growth Rate (2011-2021) 2 Global Acetylcysteine Competition by Manufacturers, Type and Application  2.1 Global Acetylcysteine Market Competition by Manufacturers  2.1.1 Global Acetylcysteine Sales and Market Share of Key Manufacturers (2011-2016)  2.1.2 Global Acetylcysteine Revenue and Share by Manufacturers (2011-2016)  2.2 Global Acetylcysteine (Volume and Value) by Type  2.2.1 Global Acetylcysteine Sales and Market Share by Type (2011-2016)  2.2.2 Global Acetylcysteine Revenue and Market Share by Type (2011-2016) Figure Picture of Acetylcysteine  Table Classification of Acetylcysteine  Figure Global Sales Market Share of Acetylcysteine by Type in 2015  Figure JP Picture  Figure USP Picture  Figure EP Picture  Table Applications of Acetylcysteine  Figure Global Sales Market Share of Acetylcysteine by Application in 2015  Figure COPD Examples  Figure CB Examples  Figure Other Examples  Figure United States Acetylcysteine Revenue and Growth Rate (2011-2021)  Figure China Acetylcysteine Revenue and Growth Rate (2011-2021)  Figure Europe Acetylcysteine Revenue and Growth Rate (2011-2021)  Figure Japan Acetylcysteine Revenue and Growth Rate (2011-2021)  Figure Global Acetylcysteine Sales and Growth Rate (2011-2021)  Figure Global Acetylcysteine Revenue and Growth Rate (2011-2021)  Table Global Acetylcysteine Sales of Key Manufacturers (2011-2016)  Table Global Acetylcysteine Sales Share by Manufacturers (2011-2016)  Figure 2015 Acetylcysteine Sales Share by Manufacturers  Figure 2016 Acetylcysteine Sales Share by Manufacturers  Table Global Acetylcysteine Revenue by Manufacturers (2011-2016)  Table Global Acetylcysteine Revenue Share by Manufacturers (2011-2016)  Table 2015 Global Acetylcysteine Revenue Share by Manufacturers  Table 2016 Global Acetylcysteine Revenue Share by Manufacturers  Table Global Acetylcysteine Sales and Market Share by Type (2011-2016)  Table Global Acetylcysteine Sales Share by Type (2011-2016)  Figure Sales Market Share of Acetylcysteine by Type (2011-2016)  Figure Global Acetylcysteine Sales Growth Rate by Type (2011-2016)  Table Global Acetylcysteine Revenue and Market Share by Type (2011-2016)  Table Global Acetylcysteine Revenue Share by Type (2011-2016) FOR ANY QUERY, REACH US @ https://www.wiseguyreports.com/enquiry/736127-global-acetylcysteine-sales-market-report-2016

Loading Bachem AG collaborators
Loading Bachem AG collaborators